GLP-1 drug hydrogels could reduce shots to once every 4 months

The GLP-1 receptor agonist drug class became a household name almost overnight thanks to the success of Novo Nordisk’s semaglutide, marketed as Wegovy for weight loss and more recently as Ozempic for type 2 diabetes. But while GLP-1s stand to rake in billions of dollars for the pharmas that make them, long-term adherence to the drugs is less than ideal, some clinical data suggests.

error: Content is protected !!